Citigroup
EDIT icon

Citigroup’s Editas Medicine EDIT Stock Holding History

Citigroup’s Portfolio EDIT Stock Details EDIT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-99,700
Closed -$6.99M – 6534
2020
Q4 		$6.99M Buy
99,700
+43,300
+77% +$1.78M ﹤0.01% 1840
2020
Q3 		$1.58M Sell
56,400
-9,200
-14% -$300K ﹤0.01% 2875
2020
Q2 		$1.94M Sell
65,600
-12,200
-16% -$319K ﹤0.01% 2845
2020
Q1 		$1.54M Buy
77,800
+2,000
+3% +$50.4K ﹤0.01% 2743
2019
Q4 		$2.24M Buy
75,800
+20,300
+37% +$507K ﹤0.01% 2846
2019
Q3 		$1.26M Buy
55,500
+6,100
+12% +$151K ﹤0.01% 3377
2019
Q2 		$1.22M Buy
49,400
+22,700
+85% +$542K ﹤0.01% 3396
2019
Q1 		$653K Buy
26,700
+6,900
+35% +$156K ﹤0.01% 3891
2018
Q4 		$450K Buy
19,800
+5,600
+39% +$152K ﹤0.01% 4241
2018
Q3 		$452K Buy
14,200
+8,100
+133% +$262K ﹤0.01% 4406
2018
Q2 		$219K Buy
6,100
+4,800
+369% +$170K ﹤0.01% 4978
2018
Q1 		$43K Buy
+1,300
New +$46.3K ﹤0.01% 6269

Other funds holding EDIT

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Citigroup's EDIT Position: Q1 2026 in Review

Citigroup increased its Editas Medicine (EDIT) stake by 45% in Q1 2026, buying an estimated $4.79K and bringing the position to 7,298 shares worth $18K. The position accounts for ﹤0.01% of the portfolio, ranked #4864.

Citigroup first reported a position in EDIT in Q1 2016 and has held it in 41 quarters since. The position peaked at $8.12M in Q2 2021. 207 funds tracked by Wall St. Rank hold EDIT as of Q1 2026.

  • Citigroup held 7,298 shares of Editas Medicine worth $18K as of Q1 2026.
  • Citigroup bought 2,261 Editas Medicine shares in Q1 2026, an estimated $4.79K.
  • Editas Medicine made up ﹤0.01% of Citigroup's portfolio in Q1 2026, its #4864 holding.
  • Citigroup first reported a position in Editas Medicine in Q1 2016 and has held it in 41 quarters since.
  • Citigroup's Editas Medicine position peaked at $8.12M in Q2 2021.
  • 207 funds tracked by Wall St. Rank held Editas Medicine as of Q1 2026.

Based on Citigroup's 13F filing for Q1 2026, filed 11 May 2026.